BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

  Business Intellilgence

Can AI Diagnose Better Than Humans?

by Illia Terpylo  (contributor )   •   July 11, 2025

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

A week ago, Microsoft released the AI Diagnostic Orchestrator (MAI-DxO), a platform designed to utilize five large language model agents functioning as a panel of virtual doctors to develop disease treatment strategies. To evaluate its capabilities, the Orchestrator was tested using 304 medical case studies sourced from the New England Journal of Medicine. MAI-DxO pushed OpenAI’s latest o3 model to solve 85.5% of them, quadrupling the success rate reported for experienced clinicians working under identical constraints.

This launch echoes the words of medical futurist Bertalan Meskó who once called artificial intelligence the “the stethoscope of the 21st century”. But AI diagnostics didn’t start with LLMs, it goes back to the 1950s, with rule-based systems and early diagnostic logic.


In this article: How Diagnostic AI Got Here — Tradition vs. Modernity — Molecular Diagnostics — Cancer Diagnostics — Infectious Diseases — Rare Genetic Diseases — Clinical Imaging — Cardiovascular Diseases — Dermatology — Respiratory Diseases — Eye Diseases — Digital Pathology — Prospects & Challenges


 

To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.

Gain full access to all of our deep dives and content archives.

 Upgrade to Pro 

Already a member? Sign in here.
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.